<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00376844</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000502033</org_study_id>
    <secondary_id>CKTO-2001-04</secondary_id>
    <secondary_id>P01.146</secondary_id>
    <secondary_id>ISRCTN16228756</secondary_id>
    <nct_id>NCT00376844</nct_id>
  </id_info>
  <brief_title>External-Beam Radiation Therapy Compared With Vaginal Brachytherapy After Surgery for Stage I Endometrial Cancer</brief_title>
  <acronym>PORTEC-2</acronym>
  <official_title>PORTEC-2, Postoperative Radiation Therapy for Endometrial Carcinoma - A Multicenter Randomised Phase III Trial Comparing External Beam Radiation and Vaginal Brachytherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: External-beam radiation therapy uses high-energy x-rays to kill tumor cells.
      Implant radiation therapy uses radioactive material placed directly into or near a tumor to
      kill tumor cells. Giving external-beam radiation therapy or implant radiation therapy after
      surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, the
      tumor may not need more treatment until it progresses. In this case, observation may be
      sufficient. It is not yet known whether radiation therapy is more effective than observation
      when given after surgery in treating stage I endometrial cancer.

      PURPOSE: This randomized phase III trial is studying external-beam radiation therapy or
      implant radiation therapy to see how well they work compared with observation in treating
      patients who have undergone surgery for stage I endometrial cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the rate of 5-year locoregional relapse in patients undergoing external-beam
           radiotherapy or vaginal brachytherapy vs observation only after surgery for stage I
           endometrial cancer.

        -  Compare 5-year rate of distant metastases in these patients.

        -  Determine overall survival rate in these patients.

        -  Determine prognostic factors for relapse and morbidity.

      OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment
      arms.

        -  Arm I: Patients undergo either vaginal brachytherapy or external-beam radiotherapy.

        -  Arm II: Patients are observed and undergo no further treatment. After completion of
           study treatment, patients are followed for approximately 83 days.

      PROJECTED ACCRUAL: A total of 400 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Exterbal beam radiation therapy versus vaginal brachytherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vaginal relapse</measure>
    <time_frame>5 years</time_frame>
    <description>total vaginal relapse and vaginal relapse as first failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of distant metastases</measure>
    <time_frame>5 years</time_frame>
    <description>total distant relapse and distant relapse as first failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>all-cause survival (and cancer-related survival)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>5 years</time_frame>
    <description>Types and severity graded according to EORTC-RTOG grading system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>5 years</time_frame>
    <description>Cancer-specific quality of life (EORTC QLQ C-30); patient reported symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic relapse</measure>
    <time_frame>5 years</time_frame>
    <description>total pelvic relapse and pelvic relapse as first failure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">427</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>External Beam Radiation Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Postoperative pelvic radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal Brachytherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Postoperative vaginal brachytherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External Beam Radiation Therapy</intervention_name>
    <arm_group_label>External Beam Radiation Therapy</arm_group_label>
    <other_name>pelvic radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Vaginal Brachytherapy</intervention_name>
    <arm_group_label>Vaginal Brachytherapy</arm_group_label>
    <other_name>internal radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Diagnosis of FIGO 1988 stage I-IIA endometrial cancer, meeting 1 of the following
             criteria:

               -  Age ≥60, stage IC grade 1 or 2 with deep (≥ 50%) myometrial invasion

               -  Age ≥60, stage IB grade 2 or 3 (with &lt; 50% myometrial invasion)

               -  Stage IIA, any age

          -  No grade 3 endometrial carcinoma with deep myometrial invasion

          -  Total abdominal hysterectomy and bilateral salpingo-oophorectomy required prior to
             randomisation

          -  WHO performance status 0-2

        EXCLUSION CRITERIA:

          -  Serous or clear cell histology or uterine sarcoma

          -  staging lymphadenectomy

          -  interval between surgery and radiotherapy &gt; 8 weeks

          -  history of previous malignant disease (except basal cell carcinoma of skin)

          -  previous radiotherapy, hormonal therapy or chemotherapy

          -  diagnosis of Chrohn's disease or ulcerative colitis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carien L. Creutzberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrials.gov/ct2/show/study/NCT00376844?term=portec&amp;cond=Endometrial+Cancer&amp;rank=1</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQ® database</description>
  </link>
  <reference>
    <citation>McCloskey SA, Tchabo NE, Malhotra HK, Odunsi K, Rodabaugh K, Singhal P, Lele S, Jaggernauth W. Adjuvant vaginal brachytherapy alone for high risk localized endometrial cancer as defined by the three major randomized trials of adjuvant pelvic radiation. Gynecol Oncol. 2010 Mar;116(3):404-7. doi: 10.1016/j.ygyno.2009.06.027. Epub 2009 Nov 27.</citation>
    <PMID>19944453</PMID>
  </reference>
  <results_reference>
    <citation>Nout RA, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Stenfert Kroese MC, Nijman HW, van de Poll-Franse LV, Creutzberg CL. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer. 2012 Jul;48(11):1638-48. doi: 10.1016/j.ejca.2011.11.014. Epub 2011 Dec 14.</citation>
    <PMID>22176868</PMID>
  </results_reference>
  <results_reference>
    <citation>Nout RA, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Stenfert Kroese MC, van Bunningen BN, Smit VT, Nijman HW, van den Tol PP, Creutzberg CL. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol. 2009 Jul 20;27(21):3547-56. doi: 10.1200/JCO.2008.20.2424. Epub 2009 Jun 22.</citation>
    <PMID>19546404</PMID>
  </results_reference>
  <results_reference>
    <citation>Nout RA, Putter H, Jürgenliemk-Schulz IM, et al.: Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: Results of the randomized PORTEC-2 trial. [Abstract] J Clin Oncol 26 (Suppl 15): A-LBA5503, 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>Nout RA, Smit VT, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Kroese MC, van Bunningen BN, Ansink AC, van Putten WL, Creutzberg CL; PORTEC Study Group. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010 Mar 6;375(9717):816-23. doi: 10.1016/S0140-6736(09)62163-2.</citation>
    <PMID>20206777</PMID>
  </results_reference>
  <results_reference>
    <citation>de Boer SM, Nout RA, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Stenfert Kroese MC, Oerlemans S, Putter H, Verhoeven-Adema KW, Nijman HW, Creutzberg CL. Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial. Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):797-809. doi: 10.1016/j.ijrobp.2015.08.023. Epub 2015 Aug 18.</citation>
    <PMID>26530748</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2006</study_first_submitted>
  <study_first_submitted_qc>September 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2006</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>Carien Creutzberg</investigator_full_name>
    <investigator_title>Professor of Radiation Oncology, Chief investigator</investigator_title>
  </responsible_party>
  <keyword>stage I endometrial carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Will be decided late 2016</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

